Select Medical Taken Private in $3.9 Billion Consortium Deal — Select Medical Holdings Corporation

Event summary

Select Medical Holdings Corporation acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS for $3.9 billion.
$16.50 per share represents an 18% premium over the unaffected share price and a 25% premium over the 90-day average closing price as of November 24, 2025.
The acquisition completed on June 30, 2026, with Select Medical's common stock ceasing trading on the NYSE effective July 1, 2026.
Current officers, including Ortenzio and Jackson, will continue to lead the business post-acquisition.

The big picture

Select Medical's acquisition by a consortium led by insiders and WCAS reflects the ongoing trend of private equity taking control of large healthcare providers. The $3.9 billion deal underscores the value in specialized rehabilitation and critical illness recovery services, particularly as private investors seek to optimize operations and expand market reach. This transaction also highlights the strategic importance of governance shifts in the healthcare sector, where private equity firms are increasingly partnering with management teams to drive growth.

What we're watching

Operational Continuity: How the consortium's operational control will impact Select Medical's critical illness recovery and rehabilitation services.
Private Equity Strategy: Whether WCAS can drive value through operational improvements and strategic acquisitions in the healthcare sector.
Market Impact: The pace at which other private equity firms target large-scale healthcare operators for take-private deals.